Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Cedars-Sinai Medical Center11 enrolled

Overview

Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of acute kidney rejection only. There is no clinical data of its use in heart transplant patients.

This is an open-labeled, prospective, non-randomized pilot-phase study of the enteric-coated, Myfortic® versus the non enteric-coated, Cellcept® in patients who are within 5 years of having undergone heart transplant surgery who are currently taking Cellcept®. After the initial screening, 20 patients who fulfill the inclusion criteria and report symptoms of gastrointestinal side-effects while taking Cellcept will be switched to Myfortic. All 20 patients will be followed closely over a period of 6 months following enrollment. Concomitant immunosuppressive therapy will continue in all patients per standard treatment protocol.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastrointestinal Symptoms Heart Transplantation

Interventions

Mycophenolate SodiumDRUG

1440mg/day (720mg by mouth, twice a day)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients of either sex aged 18 and above who have undergone successful orthotopic heart transplant surgery. 2. Patients who are currently taking Cellcept® and experiencing gastrointestinal side-effects from this standard therapy. 3. Individuals on Cellcept® with total dosage of 2 mg a day or less would be eligible to participate. 4. Patients who are able to give written informed consent. Exclusion Criteria: 1. Patients with an absolute neutrophil count \<1500 cells/mm3, and/or leukocytopenia (\<2500 cells/mm3), thrombocytopenia (\<75,000 cells/mm3) and significant anemia (hemoglobin \< 6g/dl) at the time of potential enrollment. 2. Women of childbearing potential not using the contraception method(s), as well as women who are breastfeeding. 3. Known sensitivity to the study drug or class of the study drug. 4. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study. 5. Use of any other investigational agent in the last 30 days.

Locations (1)

Cedars- Sinai Medical Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

GI Tolerability as Measured by GSRS

Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale) GSRS has 15 items, each rated on a 7-point scale from 1 (no discomfort) to 7 (very severe discomfort). GSRS total minimum value is 15; maximum value is 105. Higher scores represent greater discomfort.

Time frame: Baseline and 6 months

Secondary Outcomes

Number of Biopsy Proven Acute Rejection, Graft Loss and Death Due to Rejection.

Number of biopsy proven acute rejection, graft loss, and death due to rejection. Number of rejection episodes where rejection is defined as Grade 1B or higher on myocardial biopsy as measured by the 1990 Grading System of the International Society of Heart and Lung Transplantation for Acute Cellular Rejection. Grading system has: * grade 0 (no acute rejection) * grade 1A (Focal, mild acute rejection) * grade 1B (Diffuse, mild acute rejection) * grade 2 (Focal, moderate acute rejection) * grade 3A (multifocal moderate rejection) * grade 3B (Diffuse, borderline severe acute rejection) * grade 4 (Severe acute rejection).

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.